- Home
- MCRI vs NRIX Comparison
MCRI vs NRIX Comparison
Compare MCRI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | NRIX |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCRI | NRIX |
|---|---|---|
| Price | $94.21 | $14.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $100.50 | $30.58 |
| AVG Volume (30 Days) | 90.5K | ★ 891.7K |
| Earning Date | 04-21-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 41.41 | N/A |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $395,377,000.00 | $76,987,000.00 |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $2.21 | $26.32 |
| P/E Ratio | $17.89 | ★ N/A |
| Revenue Growth | ★ 114.40 | 99.31 |
| 52 Week Low | $69.99 | $8.18 |
| 52 Week High | $113.88 | $22.50 |
Technical Indicators
Market Signals| Indicator | MCRI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 42.98 |
| Support Level | $88.12 | $11.34 |
| Resistance Level | $99.36 | $16.47 |
| Average True Range (ATR) | 2.84 | 0.85 |
| MACD | -0.41 | 0.05 |
| Stochastic Oscillator | 3.79 | 36.53 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.